Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

50.42 +12.95 (+34.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,971,213
Open 65.09
Bid (Size) 50.55 (2)
Ask (Size) 51.50 (3)
Prev. Close 37.47
Today's Range 48.55 - 65.51
52wk Range 20.80 - 65.51
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
+93.92%
+93.92%
1 Month
+75.62%
+75.62%
3 Month
+21.29%
+21.29%
6 Month
+111.94%
+111.94%
1 Year
+93.92%
+93.92%

More News

Read More
Why Shares of Structure Therapeutics Are Soaring on Friday
Via The Motley Fool
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Via Benzinga
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
Via Investor's Business Daily
Why Shares of Structure Therapeutics Rose Monday
Via The Motley Fool
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
Via Benzinga
Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts?
Via Benzinga
This Biotech Is Developing The Next Ozempic. Should You Buy It?
Via The Motley Fool
Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years
Via The Motley Fool
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Present at Jefferies Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.